ozempic semaglutide weight loss off-label and Wegovy worldwide shortage due to use for cosmetic PDF) Examining Off-Label Prescribing of

PubMed PMID 33567185 randomized obesity trial

Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex

Data availability This article provides all the data supporting the findings of the study

Semaglutide is a prescription medication for type 2 diabetes and weight management that requires precise dosing to ensure its effectiveness and safety